ANI Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	883.37	614.38	486.82	316.39	216.14
Revenue Growth (YoY)	43.78%	26.20%	53.87%	46.38%	3.67%
Cost of Revenue	341.31	250.21	181.51	138.79	100.61
Gross Profit	542.06	364.17	305.3	177.6	115.53
Selling, General & Admin	317.75	237.24	161.7	124.04	84.29
Research & Development	51.66	44.58	34.29	22.32	11.37
Other Operating Expenses	-	-	-	-	0.78
Operating Expenses	460.83	349.55	255.77	203.33	143.7
Operating Income	81.23	14.62	49.53	-25.73	-28.17
Interest Expense	-20.06	-33.14	-35.05	-28.42	-11.95
Interest & Investment Income	-	15.53	8.11	0.37	0.02
Other Non Operating Income (Expenses)	1.93	-4.03	-0.16	0.67	-4.71
EBT Excluding Unusual Items	63.1	-7.02	22.43	-53.12	-44.8
Merger & Restructuring Charges	-	-12.4	-1.13	-5.68	-
Gain (Loss) on Sale of Investments	2.82	6.31	-	-	-
Gain (Loss) on Sale of Assets	-0.38	5.35	-	-	1.82
Asset Writedown	-0.77	-7.6	-	-0.11	-2.37
Legal Settlements	-	-	-	-	-8.75
Other Unusual Items	31.01	-6.85	-1.43	-3.76	-1.96
Pretax Income	95.79	-22.21	19.87	-62.67	-56.06
Income Tax Expense	17.45	-3.69	1.09	-14.77	-13.46
Net Income	78.34	-18.52	18.78	-47.9	-42.6
Preferred Dividends & Other Adjustments	1.16	1.63	3.3	1.63	0.19
Net Income to Common	77.18	-20.15	15.48	-49.52	-42.79
Shares Outstanding (Basic)	20	19	18	16	13
Shares Outstanding (Diluted)	21	19	18	16	13
Shares Change (YoY)	9.89%	6.18%	11.89%	29.09%	5.28%
EPS (Basic)	3.85	-1.04	0.86	-3.05	-3.40
EPS (Diluted)	3.32	-1.04	0.85	-3.05	-3.40
Free Cash Flow	171.39	47.78	110.09	-40.08	0.77
Free Cash Flow Per Share	8.07	2.47	6.05	-2.46	0.06
Gross Margin	61.36%	59.27%	62.71%	56.13%	53.45%
Operating Margin	9.20%	2.38%	10.17%	-8.13%	-13.03%
Profit Margin	8.74%	-3.28%	3.18%	-15.65%	-19.80%
Free Cash Flow Margin	19.40%	7.78%	22.61%	-12.67%	0.35%
EBITDA	172.65	82.35	109.32	33.92	19.08
EBITDA Margin	19.54%	13.40%	22.46%	10.72%	8.83%
D&A For EBITDA	91.42	67.73	59.79	59.65	47.25
EBIT	81.23	14.62	49.53	-25.73	-28.17
EBIT Margin	9.20%	2.38%	10.17%	-8.13%	-13.03%
Effective Tax Rate	18.22%	-	5.50%	-	-

Updated Feb 27, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q